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Adolescents with Polycystic Ovary Syndrome (PCOS) are at
risk of nonalcoholic fatty liver (NAFLD) and the metabolic syn-
drome. Objective and Methods: We determined the prevalence
and metabolic significance of NAFLD in adolescent girls with
PCOS. Community-based adolescents in the Western Australian
Pregnancy Cohort (Raine Cohort) Study participated in the men-
struation in teenagers study (n=244 females) between ages 14-
17 years and in a NAFLD study (n=578 females, 592 males) at
age 17 years. Assessments included questionnaires, anthropo-
metric, cardiovascular, pelvic ultrasound, abdominal ultrasound
and fasting blood tests. Two hundred and one girls had both
ovarian and liver ultrasounds. PCOS was diagnosed using NIH
criteria. NAFLD was diagnosed with liver ultrasound. Results:
The prevalence of PCOS and NAFLD in the menstruation study
were 16% and 19% respectively. Girls with PCOS had a higher
prevalence of NAFLD than those without PCOS (42.3% vs.
14.2%, p=0.001). NAFLD was more prevalent in obese girls
with PCOS compared with non-obese girls with PCOS (64.7%
vs. 0.0%, p=0.002 using waist circumference, 85.7% vs.
15.4%, p=0.004 using suprailiac skinfold thickness and 83.3%
vs. 30%, p=0.54 using body mass index (BMI)). Girls with
PCOS plus NAFLD had greater adipose tissue (determined by
body weight, waist circumference, BMI, suprailiac skinfold
thickness), serum leptin and triglycerides but lower serum
adiponectin than girls with PCOS without NAFLD (p<0.05 for
all). HOMA-IR, serum ALT, CRP, HDL-cholesterol, LDL-cholesterol
and glucose levels were similar between the two groups. Girls
with PCOS plus NAFLD had similar body weight, waist circum-
ference, waist/hip ratio, BMI, intensity of hepatic steatosis, sub-
cutaneous fat thickness, visceral fat thickness, skinfold thickness,
HOMA-IR, serum glucose, insulin, GGT, triglycerides, HDL-cho-
lesterol and adiponectin levels to boys with NAFLD (p>0.05 for
all). However, girls had higher serum CRP and leptin whilst
boys had higher ALT and AST levels and systolic blood pres-
sure. Free testosterone concentration (FT) was higher in girls
diagnosed with NAFLD than those without NAFLD (25.9 vs.
18.9 pmol/L, p=0.02), however FT was not predictive of
NAFLD after controlling for obesity. Suprailiac skinfold thickness
(odds ratio 1.16, 95% CI 1.08-1.24, p<0.001) and presence
of PCOS (odds ratio 3.87, 95% CI 1.09-13.76, p=0.04) were
independent predictors of NAFLD in the menstruation study.
Conclusions: NAFLD in adolescent females with PCOS is com-
mon and has metabolic similarities with male NAFLD. Obesity
and PCOS have a dominant effect over testosterone levels in
predicting female NAFLD.
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